SAB Biotherapeutics Inc

NASDAQ:SABS  
5.45
-0.37 (-6.36%)
Products, Regulatory

Sab Biotherapeutics Announces Sab-176 Met Its Primary Endpoint In Phase 2A Challenge Study In Adults Infected With Influenza Virus

Published: 12/01/2021 12:37 GMT
SAB Biotherapeutics Inc (SABS) - Sab Biotherapeutics Announces Sab-176 Met Its Primary Endpoint in Phase 2a Challenge Study in Adults Infected With Influenza Virus.
Sab Biotherapeutics Inc - Topline Data Show Sab-176 Achieved Statistically Significant Reductions in Viral Load and Clinical Symptoms.
Sab Biotherapeutics Inc - Sab Plans to Further Evaluate Sab-176 in a Phase 2 Influenza Clinical Trial Slated to Begin in 2q 2022.
Sab Biotherapeutics Inc - Topline Data Show Sab-176 Safe and Well-tolerated.